Management of Differentiated Thyroid Cancer: The Standard of Care

The Journal of Nuclear Medicine

article

Anca M. Avram¹  Katherine Zukotynski²  Helen Ruth Nadel³  Luca Giovanella⁴ 

[1] Division of Nuclear Medicine, Department of Radiology, University of Michigan;Departments of Medicine and Radiology, McMaster University;Lucile Packard Children’s Hospital at Stanford, Stanford University School of Medicine;Clinic for Nuclear Medicine and Competence Center for Thyroid Diseases, Imaging Institute of Southern Switzerland;Clinic for Nuclear Medicine, University Hospital and University of Zurich

关键词: differentiated thyroid cancer;    state of the art;    guidelines;    clinical management;   

DOI  :  10.2967/jnumed.121.262402

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

In the past decade, the management of differentiated thyroid cancer (DTC) underwent a paradigm shift toward the use of risk stratification with the goal of maximizing the benefit and minimizing the morbidity of radioiodine (131I) therapy. 131I therapy is guided by information derived from surgical histopathology, molecular markers, postoperative diagnostic radioiodine scintigraphy, and thyroglobulin levels. 131I is used for diagnostic imaging and therapy of DTC based on physiologic sodium-iodine symporter expression in normal and neoplastic thyroid tissue. We summarize the essential information at the core of multidisciplinary DTC management, which emphasizes individualization of 131I therapy according to the patient’s risk for tumor recurrence.

【 授权许可】

CC BY